Results
A dose-dependent increase in urinary glucose excretion (UGE) was
observed after a single dose, and the steady-state UGE was 50–60 g/day
after multiple doses in the dose range of 0.3 – 2.0 mg. DWP16001 was
rapidly absorbed with the time to peak plasma concentration of 1.0 –
3.0 hours, and eliminated with a mean elimination half-life of 13 - 29
hours. The systemic exposure of DWP16001 increased proportionally with
the dose after multiple administrations in the range of 0.1 – 2.0 mg.
DWP16001 was well tolerated in all dose groups.